Radiopharm Theranostics Ltd Logo

Radiopharm Theranostics Ltd

Developing first-in-class radiopharmaceuticals for the diagnosis and treatment of cancer.

RADX | US

Overview

Corporate Details

ISIN(s):
US75041J1016
LEI:
Country:
United States of America
Address:
LEVEL 3, 62 LYGON STREET, 3053 CARLTON VIC
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Radiopharm Theranostics is a clinical-stage biotechnology company developing a portfolio of first-in-class radiopharmaceuticals for the diagnosis and treatment of cancer. The company is advancing a diverse pipeline based on proprietary platforms—including antibodies, nanobodies, peptides, and small molecules—to address significant unmet needs in oncology. Its strategy focuses on pioneering novel oncology targets, distinguishing itself from therapies aimed at more established pathways. Key differentiators include strategic collaborations, such as a joint venture with MD Anderson Cancer Center, and a focus on operational excellence and reliable isotope supply chains.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Radiopharm Theranostics Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Radiopharm Theranostics Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Radiopharm Theranostics Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NuCana plc Logo
Develops safer anti-cancer medicines with ProTide technology to overcome cell resistance.
United States of America
NCNA
NUFORMIX PLC Logo
Repurposing drugs for fibrosis and oncology using proprietary cocrystal technology.
United Kingdom
NFX
Nurix Therapeutics, Inc. Logo
Developing protein degradation medicines to treat cancer and autoimmune diseases.
United States of America
NRIX
NUTEX Investments Plc Logo
Develops & distributes health, cosmetic & pharma products from natural ingredients globally.
Hungary
NUTEX
NutriBand Inc. Logo
Develops abuse-deterrent transdermal patches to make potent drug delivery safer.
United States of America
NTRB
Nuvalent, Inc. Logo
Designs targeted small molecule drugs for kinase-driven cancers to overcome treatment resistance.
United States of America
NUVL
Nuvation Bio Inc. Logo
A clinical-stage biopharma developing novel drugs for difficult-to-treat cancers.
United States of America
NUVB
Nxera Pharma Co., Ltd. Logo
Biopharma using SBDD tech to develop medicines for neurology and gastroenterology.
Japan
4565
ObsEva SA Logo
Developed novel therapeutics for women's reproductive health and pregnancy.
Switzerland
OBSN
OCULAR THERAPEUTIX, INC Logo
Develops hydrogel drug delivery therapies for eye diseases like wet AMD and glaucoma.
United States of America
OCUL

Talk to a Data Expert

Have a question? We'll get back to you promptly.